Biogen shakes up R&D chief role, makes Singhal permanent replacement. By Allison DeAngelis Jan. 5, 2023. Reprints. Ruby Wallau for STAT. M ore than a year after Al Sandrock was pushed out as ...

Biogen expects to do better this year on a key metric of financial health after a strong performance this summer from its newer products, including Leqembi, the closely watched drug for Alzheimer ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen’s $11 billion gain in market capitalization implies roughly $6.5 billion of sales in five years, assuming revenue split between the two companies, discounted at a rate of 10%, and valued ...

12 Healthy Protein Shakes for Weight Gain Medically reviewed by Jared Meacham, PhD., RD, CSCS — Written by Daniel Preiato, RD, CSCS — Updated on December 19, 2024 Chocolate peanut butter ...

Biogen Inc (NASDAQ: BIIB) reported its first quarter 2025 financial results on May 1, 2025, showing a 6% year-over-year revenue increase to $2.4 billion, driven by strong performance from its ...

As Biogen attempts to shake off its ill-fated Aduhelm launch, the Big Biotech is turning its attention to disgruntled shareholders. Biogen is angling to parry claims it misled investors on the ...

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter. Skip to content. Main Navigation. Search.